期刊
JOURNAL OF CHILD NEUROLOGY
卷 26, 期 3, 页码 329-333出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/0883073810380916
关键词
polypharmacy; intractable epilepsy; anticonvulsant; antiepileptic drug; seizure
资金
- Lundbeck (formerly Ovation) Pharmaceuticals
- Eisai
- UCB
- Novartis
- Questcor
Objectives: To study adding an anticonvulsant in children with uncontrolled epilepsy on >= 1 appropriate anticonvulsants. Methods: Chart review, patients with intractable epilepsy in a neurology clinic July 1, 2004 to December 31, 2007. Inclusion: Children on >= 1 stable anticonvulsant who had a second, third, or fourth anticonvulsant added. Exclusions: Noncompliance, subtherapeutic doses, and/or serum anticonvulsant levels, inappropriate anticonvulsant for seizure type, inadequate documentation, infantile spasms, or significant dosage changes in the baseline anticonvulsant(s) over the follow-up period. Patients were followed until further therapeutic changes occurred or September 30, 2008, whichever came first. Outcome: >= 50% decrease in seizure frequency. Results: Charts reviewed: 1886. Patients who met criteria: 84. Time to assessment: 4 weeks to 42 months (median 7 months). >= 50% reduction in seizure frequency: 35 of 52 patients with second agent added; 5 of 30 patients with third agent added (P = .0001). Conclusions: Worthwhile seizure reduction is reasonably likely with the addition of a second anticonvulsant, but much less likely with the addition of third anticonvulsant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据